Article Text

Download PDFPDF
DI-088 Single-tablet regimen Tenofovir/Emtricitabine/Rilpivirine: one year’s experience
  1. M De Castro Julve1,
  2. N Rudi Sola1,
  3. A Estefanell Tejero1,
  4. E Oliver Ferrer1,
  5. L Ortiz Ruiz1,
  6. L Raich Montiu1,
  7. L Borràs Trias1,
  8. C Pontes García2,
  9. MQ Gorgas Torner1
  1. 1Hospital de Sabadell, Institut Universitari Parc Taulí, Universitat Autònoma de Barcelona, Sabadell Barcelona, Pharmacy, Sabadell, Spain
  2. 2Hospital de Sabadell, Institut Universitari Parc Taulí, Universitat Autònoma de Barcelona, Sabadell Barcelona, Clinical Pharmacology Unit, Sabadell, Spain


Background Tenofovir/emtricitabine/rilpivirine (TDF/FTC/RPV) is a recently-marketed fixed-dose combination of antiretrovirals with which there is little clinical experience as yet.

Purpose To describe our clinical experience with TDF/FTC/RPV, in terms of effectiveness, adherence and causes of discontinuation after its first year of use in our hospital.

Material and methods We retrospectively collected data from medical records and the Outpatient Pharmacy Database on all patients who started TDF/FTC/RPV in our centre since its introduction in May 2013, and who had at least one year of follow-up. Baseline and one year viral load (VL) and CD4 counts were recorded for those who completed 12 months treatment with TDF/FTC/RPV. For those who did not, the reason for withdrawal and mean time on treatment were obtained. Adherence was calculated from dispensed and retrieved units, considering the period between dispensing the drugs.

Results 83 patients were treated with TDF/FTC/RPV; 60 male, mean age 45.1 years (SD10.5), 79 had previously received antiretrovirals. Four patients were lost to follow-up. Of 65 patients who completed one year of treatment, 46 of 51 who had undetectable baseline VL remained undetectable, and 12 of 14 patients with detectable baseline VL reached <20 copies/ml. Mean CD4 counts were 646 (SD 254) and 656 (SD 297) cells/mm3 at baseline and one year, respectively. The average adherence was 92% of the theoretical intake, 75% in the subgroup who had virological failure after 12 months.

Treatment with TDF/FTC/RPV was discontinued in 14 patients due to: virological failure (5), side effects (4), drug interactions (3), immunologic failure (1) and desire to become pregnant (1). The average length of treatment of these patients was 6.2 months (range 2.4–11.3 months).

Conclusion TDF/FTC/RPV was effective in terms of VL and CD4 counts in most patients after one year of treatment. Virological failure after 12 months was associated with low adherence.

References and/or acknowledgements Acknowledgments to Department of Pharmacy.

No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.